Tags

Type your tag names separated by a space and hit enter

Glypican 5 is an interferon-beta response gene: a replication study.
Mult Scler 2009; 15(8):913-7MS

Abstract

BACKGROUND

Multiple sclerosis (MS) is a chronic inflammatory disease of the central nervous system. Interferon-beta is the most usual therapy in relapsing-remiting MS. However, approximately 50% of the treated patients do not respond adequately. Very recently, a genome-wide association study on interferon-beta pharmacogenetics has described polymorphisms at several genes that are associated with response to this treatment. Our aim is to replicate the results obtained at the two loci most strongly implicated in the response to interferon-beta treatment, HAPLN1 and GPC5.

PATIENTS AND METHODS

We performed a case-control study, analyzing 199 patients with MS treated with interferon-beta for at least 2 years and at least two documented relapses over the 2 years, previous to treatment onset. Responders had neither relapses nor increase in expanded disability status scale (EDSS) over the 2-year follow-up period, whereas nonresponders had at least two relapses or an increase in EDSS of at least 1 point. We studied three single-nucleotide polymorphisms (SNPs) in the GPC5 locus and three SNPs in the HAPLN1 locus by TaqMan technology. Allelic frequencies between responders and nonresponders were compared by a chi-square test.

RESULTS

An association was found between GPC5 polymorphisms and the response to interferon-beta therapy in patients with MS, in agreement with earlier data (responder vs nonresponder patients: rs10492503, P = 0.0005). The other locus studied (HAPLN1) did not show association with treatment response to interferon-beta (all SNPs P > 0.05).

CONCLUSIONS

We confirm the association of polymorphisms within GPC5 with response to interferon-beta therapy in patients with MS.

Authors+Show Affiliations

Clinical Immunology Department, Hospital Clínico San Carlos, Madrid, Spain.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

19556317

Citation

Cénit, M D C., et al. "Glypican 5 Is an Interferon-beta Response Gene: a Replication Study." Multiple Sclerosis (Houndmills, Basingstoke, England), vol. 15, no. 8, 2009, pp. 913-7.
Cénit MD, Blanco-Kelly F, de las Heras V, et al. Glypican 5 is an interferon-beta response gene: a replication study. Mult Scler. 2009;15(8):913-7.
Cénit, M. D., Blanco-Kelly, F., de las Heras, V., Bartolomé, M., de la Concha, E. G., Urcelay, E., ... Martínez, A. (2009). Glypican 5 is an interferon-beta response gene: a replication study. Multiple Sclerosis (Houndmills, Basingstoke, England), 15(8), pp. 913-7. doi:10.1177/1352458509106509.
Cénit MD, et al. Glypican 5 Is an Interferon-beta Response Gene: a Replication Study. Mult Scler. 2009;15(8):913-7. PubMed PMID: 19556317.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Glypican 5 is an interferon-beta response gene: a replication study. AU - Cénit,M D C, AU - Blanco-Kelly,F, AU - de las Heras,V, AU - Bartolomé,M, AU - de la Concha,E G, AU - Urcelay,E, AU - Arroyo,R, AU - Martínez,A, Y1 - 2009/06/25/ PY - 2009/6/27/entrez PY - 2009/6/27/pubmed PY - 2009/10/9/medline SP - 913 EP - 7 JF - Multiple sclerosis (Houndmills, Basingstoke, England) JO - Mult. Scler. VL - 15 IS - 8 N2 - BACKGROUND: Multiple sclerosis (MS) is a chronic inflammatory disease of the central nervous system. Interferon-beta is the most usual therapy in relapsing-remiting MS. However, approximately 50% of the treated patients do not respond adequately. Very recently, a genome-wide association study on interferon-beta pharmacogenetics has described polymorphisms at several genes that are associated with response to this treatment. Our aim is to replicate the results obtained at the two loci most strongly implicated in the response to interferon-beta treatment, HAPLN1 and GPC5. PATIENTS AND METHODS: We performed a case-control study, analyzing 199 patients with MS treated with interferon-beta for at least 2 years and at least two documented relapses over the 2 years, previous to treatment onset. Responders had neither relapses nor increase in expanded disability status scale (EDSS) over the 2-year follow-up period, whereas nonresponders had at least two relapses or an increase in EDSS of at least 1 point. We studied three single-nucleotide polymorphisms (SNPs) in the GPC5 locus and three SNPs in the HAPLN1 locus by TaqMan technology. Allelic frequencies between responders and nonresponders were compared by a chi-square test. RESULTS: An association was found between GPC5 polymorphisms and the response to interferon-beta therapy in patients with MS, in agreement with earlier data (responder vs nonresponder patients: rs10492503, P = 0.0005). The other locus studied (HAPLN1) did not show association with treatment response to interferon-beta (all SNPs P > 0.05). CONCLUSIONS: We confirm the association of polymorphisms within GPC5 with response to interferon-beta therapy in patients with MS. SN - 1352-4585 UR - https://www.unboundmedicine.com/medline/citation/19556317/Glypican_5_is_an_interferon_beta_response_gene:_a_replication_study_ L2 - http://journals.sagepub.com/doi/full/10.1177/1352458509106509?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub=pubmed DB - PRIME DP - Unbound Medicine ER -